Fortitude Family Office’s Tango Therapeutics TNGX Stock Holding History

Fortitude Family Office’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.74K	Hold	310	–	–	﹤0.01%	1346
2026 Q2	$9.69K	Buy	310 +180	+138%	+$4.45K	﹤0.01%	788
2026 Q1	$2.72K	Buy	+130	New	+$1.81K	﹤0.01%	1165
2025 Q2	–	Sell	-1,198	Closed	-$1.64K	–	2133
2025 Q1	$1.64K	Hold	1,198	–	–	﹤0.01%	950
2024 Q4	$3.7K	Buy	1,198 +569	+90%	+$2.64K	﹤0.01%	915
2024 Q3	$4.84K	Hold	629	–	–	﹤0.01%	797
2024 Q2	$5.4K	Buy	629 +139	+28%	+$1.07K	﹤0.01%	564
2024 Q1	$3.89K	Hold	490	–	–	﹤0.01%	693
2023 Q4	$4.85K	Buy	+490	New	+$4.25K	﹤0.01%	652

Other funds holding TNGX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Fortitude Family Office's TNGX Position: Q3 2026 in Review

Fortitude Family Office held its Tango Therapeutics (TNGX) position steady in Q3 2026 at 310 shares worth $7.74K. The position accounts for ﹤0.01% of the portfolio, ranked #1346.

Fortitude Family Office first reported a position in TNGX in Q4 2023 and has held it in 9 quarters since. The position peaked at $9.69K in Q2 2026. 8 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

Fortitude Family Office held 310 shares of Tango Therapeutics worth $7.74K as of Q3 2026.
Fortitude Family Office left its Tango Therapeutics share count unchanged in Q3 2026.
Tango Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1346 holding.
Fortitude Family Office first reported a position in Tango Therapeutics in Q4 2023 and has held it in 9 quarters since.
Fortitude Family Office's Tango Therapeutics position peaked at $9.69K in Q2 2026.
8 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.